Simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer: Interim results from a phase I/II prospective study
Abstract Background This was a single institute, phase I/II study of salvage chemoradiotherapy (CRT) with simultaneous integrated boost in patients with mediastinal lymph node (LN) recurrence after esophagectomy. Methods Patients who presented with a clinical diagnosis of ≤5 mediastinal LN recurrenc...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-04-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13891 |
| _version_ | 1818339103521898496 |
|---|---|
| author | Wei‐xiang Qi Siyue Zheng Lu Cao Cheng Xu Shengguang Zhao Jiayi Chen |
| author_facet | Wei‐xiang Qi Siyue Zheng Lu Cao Cheng Xu Shengguang Zhao Jiayi Chen |
| author_sort | Wei‐xiang Qi |
| collection | DOAJ |
| description | Abstract Background This was a single institute, phase I/II study of salvage chemoradiotherapy (CRT) with simultaneous integrated boost in patients with mediastinal lymph node (LN) recurrence after esophagectomy. Methods Patients who presented with a clinical diagnosis of ≤5 mediastinal LN recurrence received three consecutive levels of radiotherapy dose for the recurrences. Level 1: 58.8 Gy/2.1 Gy/28 fractions, Level 2: 64.4 Gy/2.3 Gy/28 fractions and Level 3: 70 Gy/2.5 Gy/28 fractions. Results A total of 17 patients (10 patients in phase I and 7 patients in phase II) were enrolled in the present study between June 2019 and July 2020. The median duration from surgery to initial recurrence was four months (range: 3–43 months). The most common site of recurrence according to JES was 106recR, accounting for 35%. Dose‐limiting toxicity was not observed during three‐month follow‐up after completion of irradiation. The most common hematological toxicities were leukocytopenia and anemia. The most common nonhematological toxicity was esophagitis. The ORR according to RECIST was 58.8% (CR: seven patients; PR: three patients). With a median follow‐up of 15 months (95% CI: 7–16 months), all patients were still alive. Among them, two patients who received a level 1 dose and one patient who received a level III dose developed multiple lung metastases after salvage CRT, and another patient who received a level 1 dose developed an out‐of‐field recurrence in the left cervical lymph node area. Another patient who received a level III dose developed chest wall recurrence after salvage CRT. Conclusions The regimen of salvage CRT using the simultaneous integrated boost (SIB) technique (70 Gy/2.5 Gy/28F) for mediastinal lymph node recurrence in ESCC patients after esophagectomy is feasible and well tolerated. |
| first_indexed | 2024-12-13T15:21:41Z |
| format | Article |
| id | doaj.art-7de68f21ef804816852e9607f04d58fb |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-13T15:21:41Z |
| publishDate | 2021-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-7de68f21ef804816852e9607f04d58fb2022-12-21T23:40:33ZengWileyThoracic Cancer1759-77061759-77142021-04-011281180118610.1111/1759-7714.13891Simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer: Interim results from a phase I/II prospective studyWei‐xiang Qi0Siyue Zheng1Lu Cao2Cheng Xu3Shengguang Zhao4Jiayi Chen5Department of Radiation Oncology, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai ChinaDepartment of Radiation Oncology, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai ChinaDepartment of Radiation Oncology, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai ChinaDepartment of Radiation Oncology, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai ChinaDepartment of Radiation Oncology, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai ChinaDepartment of Radiation Oncology, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai ChinaAbstract Background This was a single institute, phase I/II study of salvage chemoradiotherapy (CRT) with simultaneous integrated boost in patients with mediastinal lymph node (LN) recurrence after esophagectomy. Methods Patients who presented with a clinical diagnosis of ≤5 mediastinal LN recurrence received three consecutive levels of radiotherapy dose for the recurrences. Level 1: 58.8 Gy/2.1 Gy/28 fractions, Level 2: 64.4 Gy/2.3 Gy/28 fractions and Level 3: 70 Gy/2.5 Gy/28 fractions. Results A total of 17 patients (10 patients in phase I and 7 patients in phase II) were enrolled in the present study between June 2019 and July 2020. The median duration from surgery to initial recurrence was four months (range: 3–43 months). The most common site of recurrence according to JES was 106recR, accounting for 35%. Dose‐limiting toxicity was not observed during three‐month follow‐up after completion of irradiation. The most common hematological toxicities were leukocytopenia and anemia. The most common nonhematological toxicity was esophagitis. The ORR according to RECIST was 58.8% (CR: seven patients; PR: three patients). With a median follow‐up of 15 months (95% CI: 7–16 months), all patients were still alive. Among them, two patients who received a level 1 dose and one patient who received a level III dose developed multiple lung metastases after salvage CRT, and another patient who received a level 1 dose developed an out‐of‐field recurrence in the left cervical lymph node area. Another patient who received a level III dose developed chest wall recurrence after salvage CRT. Conclusions The regimen of salvage CRT using the simultaneous integrated boost (SIB) technique (70 Gy/2.5 Gy/28F) for mediastinal lymph node recurrence in ESCC patients after esophagectomy is feasible and well tolerated.https://doi.org/10.1111/1759-7714.13891clinical trialesophageal cancerrecurrencesalvage chemoradiotherapy |
| spellingShingle | Wei‐xiang Qi Siyue Zheng Lu Cao Cheng Xu Shengguang Zhao Jiayi Chen Simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer: Interim results from a phase I/II prospective study Thoracic Cancer clinical trial esophageal cancer recurrence salvage chemoradiotherapy |
| title | Simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer: Interim results from a phase I/II prospective study |
| title_full | Simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer: Interim results from a phase I/II prospective study |
| title_fullStr | Simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer: Interim results from a phase I/II prospective study |
| title_full_unstemmed | Simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer: Interim results from a phase I/II prospective study |
| title_short | Simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer: Interim results from a phase I/II prospective study |
| title_sort | simultaneous integrated boost for mediastinal lymph node recurrence after radical surgery for esophageal cancer interim results from a phase i ii prospective study |
| topic | clinical trial esophageal cancer recurrence salvage chemoradiotherapy |
| url | https://doi.org/10.1111/1759-7714.13891 |
| work_keys_str_mv | AT weixiangqi simultaneousintegratedboostformediastinallymphnoderecurrenceafterradicalsurgeryforesophagealcancerinterimresultsfromaphaseiiiprospectivestudy AT siyuezheng simultaneousintegratedboostformediastinallymphnoderecurrenceafterradicalsurgeryforesophagealcancerinterimresultsfromaphaseiiiprospectivestudy AT lucao simultaneousintegratedboostformediastinallymphnoderecurrenceafterradicalsurgeryforesophagealcancerinterimresultsfromaphaseiiiprospectivestudy AT chengxu simultaneousintegratedboostformediastinallymphnoderecurrenceafterradicalsurgeryforesophagealcancerinterimresultsfromaphaseiiiprospectivestudy AT shengguangzhao simultaneousintegratedboostformediastinallymphnoderecurrenceafterradicalsurgeryforesophagealcancerinterimresultsfromaphaseiiiprospectivestudy AT jiayichen simultaneousintegratedboostformediastinallymphnoderecurrenceafterradicalsurgeryforesophagealcancerinterimresultsfromaphaseiiiprospectivestudy |